

Xiaonan Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9269023/publications.pdf>

Version: 2024-02-01

22
papers

1,229
citations

567144

15
h-index

677027

22
g-index

22
all docs

22
docs citations

22
times ranked

2459
citing authors

#	ARTICLE	IF	CITATIONS
1	Iron Chelator VLX600 Inhibits Mitochondrial Respiration and Promotes Sensitization of Neuroblastoma Cells in Nutrition-Restricted Conditions. <i>Cancers</i> , 2022, 14, 3225.	1.7	2
2	Targeting Mitochondrial Metabolism in Clear Cell Carcinoma of the Ovaries. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4750.	1.8	8
3	Targeting Loss of Heterozygosity: A Novel Paradigm for Cancer Therapy. <i>Pharmaceuticals</i> , 2021, 14, 57.	1.7	27
4	Induction of ER Stress in Acute Lymphoblastic Leukemia Cells by the Deubiquitinase Inhibitor VLX1570. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4757.	1.8	13
5	Drug Development Targeting the Ubiquitinâ€“Proteasome System (UPS) for the Treatment of Human Cancers. <i>Cancers</i> , 2020, 12, 902.	1.7	75
6	Oxidative Stress Induced by the Deubiquitinase Inhibitor b-AP15 Is Associated with Mitochondrial Impairment. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-11.	1.9	10
7	UNC-45A is preferentially expressed in epithelial cells and binds to and co-localizes with interphase MTs. <i>Cancer Biology and Therapy</i> , 2019, 20, 1304-1313.	1.5	14
8	Repurposing of auranofin: Thioredoxin reductase remains a primary target of the drug. <i>Biochimie</i> , 2019, 162, 46-54.	1.3	113
9	Proteasome inhibitor b-AP15 induces enhanced proteotoxicity by inhibiting cytoprotective aggresome formation. <i>Cancer Letters</i> , 2019, 448, 70-83.	3.2	21
10	Irreversible inhibition of cytosolic thioredoxin reductase 1 as a mechanistic basis for anticancer therapy. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	147
11	The deubiquitinase inhibitor b-AP15 induces strong proteotoxic stress and mitochondrial damage. <i>Biochemical Pharmacology</i> , 2018, 156, 291-301.	2.0	22
12	Estrogen Receptor $\hat{1}^2$ as a Therapeutic Target in Breast Cancer Stem Cells. <i>Journal of the National Cancer Institute</i> , 2017, 109, 1-14.	3.0	62
13	MYC is downregulated by a mitochondrial checkpoint mechanism. <i>Oncotarget</i> , 2017, 8, 90225-90237.	0.8	13
14	Iron chelators target both proliferating and quiescent cancer cells. <i>Scientific Reports</i> , 2016, 6, 38343.	1.6	52
15	Eradicating Quiescent Tumor Cells by Targeting Mitochondrial Bioenergetics. <i>Trends in Cancer</i> , 2016, 2, 657-663.	3.8	17
16	IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells. <i>Blood</i> , 2016, 128, 1475-1489.	0.6	136
17	Targeting Mitochondrial Function to Treat Quiescent Tumor Cells in Solid Tumors. <i>International Journal of Molecular Sciences</i> , 2015, 16, 27313-27326.	1.8	53
18	Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1504-1516.	1.9	122

#	ARTICLE	IF	CITATIONS
19	Label-free detection and dynamic monitoring of drug-induced intracellular vesicle formation enabled using a 2-dimensional matched filter. <i>Autophagy</i> , 2014, 10, 57-69.	4.3	3
20	Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments. <i>Nature Communications</i> , 2014, 5, 3295.	5.8	197
21	Induction of Tumor Cell Apoptosis by a Proteasome Deubiquitinase Inhibitor Is Associated with Oxidative Stress. <i>Antioxidants and Redox Signaling</i> , 2014, 21, 2271-2285.	2.5	67
22	The 19S Deubiquitinase Inhibitor b-AP15 Is Enriched in Cells and Elicits Rapid Commitment to Cell Death. <i>Molecular Pharmacology</i> , 2014, 85, 932-945.	1.0	55